oxybutynin transdermal / Generic mfg. - LARVOL DELTA

Patching Up the Confusion: Rare Use of Rivastigmine Patch for Oxybutynin Overdose in a Pediatric Patient (AAP-NCE 2025) - "This is one of few reported cases demonstrating effective use of transdermal rivastigmine to manage anticholinergic poisoning in a pediatric patient. Transdermal rivastigmine patch should be explored as an option for reversal of anticholinergic toxicity in pediatric patients, especially those where oral administration is not feasible and where physostigmine is unavailable."

Clinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease • Pediatrics • Psychiatry • Urinary Incontinence • Urology

Efficacy and Safety of Treatments for Primary Palmar Hyperhidrosis: A Systematic Review Assessing Patient-Centric Outcomes. (PubMed, Dermatol Res Pract) - "The treatments assessed included oral and topical oxybutynin, iontophoresis, botulinum toxin A injections, photodynamic therapy (PDT) and endoscopic thoracic sympathectomy (ETS)... This review highlights the efficacy of several therapeutic approaches for PH though most treatments are hindered by significant adverse effects or practical limitations. Future research should prioritize long-term studies and standardized outcome measures to guide clinical decision-making more effectively."

Journal • Review • Dermatology

Transdermal Versus Oral Oxybutynin in Pediatric OAB (clinicaltrials.gov) - P=N/A | N=90 | Completed | Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital

New trial • Overactive Bladder • Pediatrics

Electrochemical investigation of oxytrol in fizzy drinks and juices via graphene and polymer printed PVC by ANOVA and design expert. (PubMed, Sci Rep) - "Additionally, comprise its concentration in samples, including canned drinks such as Coca-Cola, and natural juices like apple, berry, and pomegranate, using high-performance liquid chromatography (HPLC) outcomes and proposed method. The recovery percentages ranged from 98.00 to 99.27%, with satisfactory low standard and relative standard deviation values < 5, via statistical ANOVA, Design Expert for producing an ideal model with other parameters."

Journal • Otorhinolaryngology

Topical oxybutynin deodorant for axillary hyperhidrosis: a topic or a systemic effect? Rationale and design of the phase II today trial. (PubMed, J Vasc Bras) - "The primary efficacy outcome will be the evaluation of the effectiveness of topical oxybutynin spray in treating hyperhidrosis. The TODAY trial will generate high-quality evidence on the effects of topical oxybutynin, assessing whether its impact is local or systemic in patients with axillary hyperhidrosis."

Journal • P2 data • Review • Dermatology

BoNT-A is an effective and safe treatment for PPH: A retrospective case series of 129 patients (EADV 2024) - "Predominantly, 115 patients (89.1%) received onabotulinumtoxin-A, nine (7.0%) abobotulinumtoxin-A, and five (3.9%) both in successive sessions...Recent trials have also explored oxybutynin gel for PPH... Various studies have investigated the impact of BoNT-A treatment on the quality of life (QoL) of patients with primary hyperhidrosis. A significant reduction in Dermatology Life Quality Index (DLQI) was found in patients treated with BoNT-A. Therapeutic modalities for PPH include topical agents, iontophoresis, and BoNT-A injections."

Retrospective data • Anesthesia • Dermatology • Pain

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder (clinicaltrials.gov) - P4 | N=52 | Completed | Sponsor: AbbVie | N=19 ➔ 52

Enrollment change • Pediatrics

Multiple widespread fixed drug eruption caused by in a transdermal therapeutic system. (PubMed, Contact Dermatitis) - No abstract available

Biomarker • Clinical • Journal • Retrospective data • Review

TODAY: Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect? (clinicaltrials.gov) - P2 | N=17 | Recruiting | Sponsor: Samantha Rodrigues Camargo Neves de Moura | Not yet recruiting ➔ Recruiting | N=60 ➔ 17 | Trial completion date: Jun 2022 ➔ Aug 2024 | Trial primary completion date: Mar 2022 ➔ Jun 2024

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Dermatology

A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin. (PubMed, Acta Neuropathol) - P3 | "Systemic (3-10 mg/kg/day s.c.) and topical (3% gel daily) oxybutynin reversed paw heat hypoalgesia in the STZ and db/db mouse models of diabetes and reversed paw tactile allodynia in STZ-diabetic rats...This proof-of-concept study indicates that muscarinic antagonists suitable for long-term use may offer a novel therapeutic opportunity for treatment of diabetic neuropathy. Trial registry number: NCT03050827."

Biomarker • Clinical • Clinical protocol • Journal • Observational data • Preclinical • Retrospective data • Review • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Neuralgia • Overactive Bladder • Pain • Peripheral Neuropathic Pain • Type 2 Diabetes Mellitus

Topical oxybutynin for hyperhidrosis: A systematic review (AAD 2024) - "Of the 416 patients treated with oxybutynin, application site reactions (n=71), xerostomia (n=9), and thirst (n=9) were the most frequently reported adverse effects. Overall, topical oxybutynin appears to be a safe and effective therapy for patients with primary hyperhidrosis."

Review • Dental Disorders • Dermatology • Xerostomia

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder (clinicaltrials.gov) - P4 | N=19 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed | Trial primary completion date: Dec 2023 ➔ Aug 2023

Trial completion • Trial primary completion date • Pediatrics

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder (clinicaltrials.gov) - P4 | N=19 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting | N=58 ➔ 19

Enrollment change • Enrollment closed • Pediatrics

Analyzing Access and Costs of Oral Medications for Overactive Bladder (OAB): Uncovering Disparities. (PubMed, Urology) - "We evaluated coverage, out-of-pocket costs, total yearly costs, and utilization management for OAB medications to make pricing more transparent. While selective medications may be "covered", coverage does not translate into affordable drug prices."

Journal • Overactive Bladder

Topical Oxybutynin 3% Gel Versus Aluminum Chloride 15% Lotion in Treatment of Primary Focal Hyperhidrosis. (PubMed, Dermatol Pract Concept) - "Oxybutynin 3% gel could be considered as a promising treatment modality for hyperhidrosis with higher efficacy than aluminum chloride 15% lotion and lower recurrence rate."

Journal • Dermatology

Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial. (PubMed, J Cosmet Dermatol) - "Oxybutynin gel and nanoemulgel offer equal safety and similar efficacy in reducing the disease severity and increasing the quality of life of patients with palmar hyperhidrosis."

Clinical • Journal • Dermatology

A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study in Japan. (PubMed, J Am Acad Dermatol) - "In patients with PPHH, 20% OL is superior to placebo in reducing palmar sweat volume."

Journal • P3 data • Dermatology

Drugs for overactive bladder. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Overactive Bladder

A Randomized Crossover Trial Comparing the Efficacy and Safety of Fesoterodine and Extended-Release Oxybutynin in Children with Overactive Bladder with 12-month Extension on Fesoterodine: The FOXY Study (AUA 2019) - No abstract available.

Clinical

Efficacy, Safety and Quality of Life of Oxybutynin versus Aluminum Chloride Hexahydrate in Treating Primary Palmar Hyperhidrosis. (PubMed, Indian J Dermatol) - "This study aimed to compare the efficacy and safety of oral oxybutynin versus topical aluminum chloride hexahydrate (ACH) in treating primary palmar hyperhidrosis...Treatment of primary palmar hyperhidrosis with oxybutynin is a good initial alternative for treatment given that it gives better results and much more improvement in QOL when compared to topical ACH. QOL questionnaire and clinical grading should also be considered as useful tools in the assessment of response to treatment."

HEOR • Journal • Dermatology • Xerostomia

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder (clinicaltrials.gov) - P4 | N=58 | Recruiting | Sponsor: AbbVie | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Nov 2022 ➔ Nov 2023

Trial completion date • Trial primary completion date • Pediatrics

Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats. (PubMed, Front Bioeng Biotechnol) - "Compared to the model, OCP50, CP100, and OCP100 relieved the overactive bladder and inhibited the expression of Orail and STIM1. Oxybutynin hydrogel could provide relief to overactive bladder by decreasing the expression of Orail and STIM1 in rats."

Journal • Preclinical • Overactive Bladder • STIM1

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder (clinicaltrials.gov) - P4 | N=58 | Recruiting | Sponsor: AbbVie | Trial primary completion date: May 2022 ➔ Nov 2022

Trial primary completion date • Pediatrics

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder (clinicaltrials.gov) - P4 | N=58 | Recruiting | Sponsor: AbbVie | Trial completion date: Jul 2022 ➔ Dec 2022

Trial completion date • Pediatrics

Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome. (PubMed, Pharm Dev Technol) - "In addition, selectively blocking hair follicles test evidenced that hair follicles pathway played an important role in OXY-NS transdermal delivery. In general, by virtue of excellent drug loading, low toxicity and ease of scale-up, OXY-NG is a promising strategy to ameliorate skin permeation of insoluble OXY for better transdermal treatment for OAB, hence increasing its bioavailability, reducing adverse effects and achieving good patient compliance."

Journal • Overactive Bladder